Contraceptive Pills and Hormone Medicines — With Cancer Drugs

It depends on two things: your cancer type and the specific drugs in your regimen. For hormone-sensitive cancers, the oestrogen in the combined pill creates an additional concern and most oncologists will recommend stopping it. For other cancer types, the question is whether your specific chemotherapy drugs affect the liver enzymes that break the pill down — some do, some do not. Do not assume the pill is safe because it is not a cancer drug. Tell your team before treatment starts and ask directly: is my current contraception still reliable on this regimen?

Yes. Tamoxifen and aromatase inhibitors work by reducing oestrogen's effect on hormone-sensitive cancer cells. The combined pill delivers oestrogen into your system, which works against that aim. NCCN and ESMO guidance recommends avoiding oestrogen-containing contraception if you are taking either of these medicines. Your oncologist will suggest an alternative — the copper IUD is often the preferred option in this setting.

For several cancer drugs, especially some used in blood cancers and certain targeted therapies, the pill alone is not considered sufficient. These drugs can cause serious harm to a developing pregnancy, and guidance from NCCN, ESMO and CDSCO-recognised prescribing conditions requires a highly effective method — not the pill alone, and for some drugs, two methods simultaneously. Your oncologist will tell you which category your treatment falls into. This is not a decision to make without them.

Treatment can reduce fertility, but not reliably enough to use as a contraception strategy — especially during active treatment, when the extent of any effect is unpredictable. An unplanned pregnancy during cancer treatment is dangerous. Some drugs must be stopped immediately if pregnancy occurs, which can disrupt your treatment at a critical point. Unless your oncologist tells you explicitly that contraception is no longer needed, continue using it.

Possibly yes. Some cancer drugs are present in semen at levels that could affect a developing pregnancy, and for those drugs, guidance from NCCN and ESMO recommends that the partners of male patients use effective contraception during treatment and for a period afterwards. Ask your husband's oncologist directly: does this drug require contraception on our side? Do not assume the requirement only applies to the person taking the drug.

The hormonal coil releases a progestogen locally into the uterus with very little entering the bloodstream, and it contains no oestrogen. For many cancer types, this makes it a more acceptable option than the combined pill. It is also not subject to the liver-enzyme interactions that make the combined pill unreliable on some treatments. However, for cancers where any progestogen exposure is a concern — such as some breast cancers or endometrial cancer — your oncologist will want to assess it specifically. Ask whether it is suitable for your situation.

The mini-pill avoids oestrogen, which removes that specific concern for hormone-sensitive cancers — though whether any progestogen exposure matters depends on your cancer type, and your oncologist will advise. However, the mini-pill is still processed by liver enzymes and is affected by cancer drugs that speed those enzymes up. Because the mini-pill already relies on a precise daily timing window, any increase in how fast it is broken down reduces its reliability further. Have it reviewed as part of your full medicine list rather than assuming it is safe.

Not necessarily, but your oncologist needs to know. This includes HRT for menopause, hormones for gender-affirming care, or any medicine containing oestrogen or progestogen prescribed for another reason. Whether you continue, adjust, or pause depends on your cancer type, your treatment, and what the hormone therapy is doing for you. Do not stop without medical guidance — stopping some hormone therapies abruptly causes significant symptoms of its own. Bring the packaging or prescription to your next appointment.